SKYRIZI

BIOLOGICAL2 trials

Sponsors

Istituto Clinico Humanitas, Chong Kun Dang Pharmaceutical

Conditions

Psoriasis

Phase 1

Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants

RecruitingNCT07258745

Chong Kun Dang PharmaceuticalPsoriasis

Start: 2025-11-26End: 2026-09-30Target: 213Updated: 2025-12-19

Phase 4

Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity

Istituto Clinico HumanitasPsoriasis

Start: 2021-01-25End: 2022-01-31Target: 240Updated: 2021-01-29